 This is a special drug use surveillance on long-term use of alogliptin with a 1-year 12-month observational period, designed to investigate the safety and efficacy of long-term combination therapy with alogliptin and thiazolidinediones in patients with type 2 diabetes mellitus in a routine clinical setting. 